Kailera Therapeutics prices IPO at $16 per share

Kailera Therapeutics Inc. (NASDAQ: KLRA) announced the pricing of its initial public offering at $16.00 per share for 39,062,500 shares of common stock. The biotechnology company, which focuses on obesity treatments, expects to raise $625.0 million in gross proceeds before underwriting discounts and offering expenses.

The company's stock is scheduled to begin trading on the Nasdaq Global Select Market on April 17, 2026, with the offering expected to close on April 20, 2026, subject to customary closing conditions. Kailera has granted underwriters a 30-day option to purchase up to an additional 5,859,375 shares at the IPO price minus underwriting discounts and commissions.

J.P. Morgan, Jefferies, Leerink Partners, TD Cowen and Evercore ISI are serving as joint book-running managers for the offering, while William Blair is acting as lead manager.

The Securities and Exchange Commission declared effective a registration statement on Form S-1 (File No. 333-294690) for the offering on April 16, 2026. The Waltham, Massachusetts-based company describes itself as an advanced clinical-stage biotechnology firm.

All shares in the offering are being sold by Kailera, according to the company's statement.

You May Also Be Interested In

• Absci prices $100M stock offering with Eli Lilly among investors
• Cardinal Infrastructure Group proposes stock offering of 3.75M shares
• TOYO Co. launches $50M direct offering for Texas solar facility